Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

 
• By Brenda Sandburg
  
Neuroblastoma
FDA advisory committee favors further research on potential surrogate endpoint for high-risk neuroblastoma • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers